Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-Dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism.

Trial Profile

Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-Dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2011

At a glance

  • Drugs Cilostazol (Primary) ; Clopidogrel (Primary) ; Aspirin
  • Indications Myocardial infarction; Stent thrombosis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms ACCEL-AMI-CYP2C19
  • Most Recent Events

    • 28 Jul 2011 Results presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis.
    • 21 Feb 2011 Primary endpoint 'Platelet-aggregation' has been met
    • 10 Nov 2009 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top